AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 7 - (NewsRx.com & NewsRx.net) -- Results of a meta-analysis suggest an association between levels of insulin-like growth factor (IGF)-I and IGF-binding proteins and development of premenopausal breast cancer.
"IGFs are peptide hormones involved in the regulation of cell proliferation, differentiation, and apoptosis. IGFs are regulated by endocrine and paracrine mechanisms; however, their action in tissue is determined by circulating levels and local production of IGFs and IGF-binding proteins (IGFBPs). Some, but not all, epidemiologic studies have associated high circulating levels of IGF-I with increased risk of breast cancer among premenopausal women," wrote R.H. Shi and colleagues, Louisiana State University (LSU).
Shi's team performed a meta-analysis of studies in the literature "[t]o evaluate the overall association of IGF-I and IGFBP-3 levels with breast cancer risk." Sixteen epidemiologic and clinical studies were evaluated.
"Analyses were performed for all women as well as for pre- and postmenopausal women separately. Hedges' standardized mean differences (HSMDs) and odds ratios (ORs) were used to estimate the effect of IGF-I and IGFBP-3," the researchers explained.
"Data analysis showed that circulating levels of lGF-I were not significantly higher in breast cancer patients than in controls for all women and for the postmenopausal group (HSMD = 0.024 and ...
Source: HighBeam Research, Meta-analysis supports IGF-I and IGFBP-3 level link with...